Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease

Sawada, Hideyuki; Oeda, Tomoko; Umemura, Atsushi; Tomita, Satoshi; Kohsaka, Masayuki; Park, Kwiyoung; Yamamoto, Kenji; Sugiyama, Hiroshi

doi:10.1371/journal.pone.0134118

Cited by 55 publications

(46 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Umemura et al conducted a retrospective study and found out that the CRP level was associated with the motor function during 5 different follow-up periods in PD patients; and reported that this relationship was independent from drug usage and gender 21 . Another retrospective study by same research group revealed that the CRP levels were independent from the disease duration and the incidence of the diseaserelated mortality 22 . Song et al found CRP levels are higher in PD patients 23 .…”

Section: Discussionmentioning

confidence: 95%

Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson's disease

Solmaz¹,

Genç²,

Aksoy³

et al. 2018

Cukurova Medical Journal

View full text Add to dashboard Cite

ÖzPurpose: We aimed to investigate the systemic inflammation status by analyzing the Neutrophil/Lymphocyte (N/L) ratio, Erythrocyte Sedimentation Rate (ESR), and C -reactive protein (CRP) in patients with Parkinson's disease (PD). Materials and Methods: 101 PD patients, and 60 healthy subjects of similar age and gender were include in this study. The demographic data and duration of the disease, the drugs, duration of usage of Parkinson drugs, Hoehn-Yahr stage were noted. After full neurological examination blood samples are collected and neutrophil, lymphocyte counts, high sensitive CRP, ESR levels are detected. Results: The N/L ratio and the CRP levels were statistically higher in Parkinson's group. There was a statistically significant but weak positive correlation between the CRP levels and the N/L ratio with the disease duration. Similarly, there was a statistically significant but weak positive correlation between the CRP levels and the N/L ratios with Hoehn-Yahr stages. When the N/L rates of the Parkinson's patients were correlated with the CRP and the ESR levels separately, it was observed that there was a weak but statistically significant correlation between the CRP and the N/L ratio Conclusion: N/L ratio, and CRP levels, which are very important indicators of peripheral inflammation, was higher in PD. Our findings suggest that these biochemical markers may have a predictive value for the diagnosis of PD.Amaç: Parkinson hastalığı (PH) olan kişilerin kanlarında nötrofil/lenfosit (N/L) oranları, sedimentasyon hızı (ESR), C-reaktif protein (CRP) düzeylerini sağlıklı kişilerle karşılaştırarak değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamıza benzer yaş ve cinsiyetten 101 PH ve 60 sağlıklı gönüllü katılımcı aldık. Hastaların sosyodemografik verileri, hastalık süreleri, kullandığı ilaçlar ve Hoehn-Yahr evreleri kaydedildi. Tam bir nörolojik muayeneden sonar hastaların kan örnekleri alınarak, nötrofil ve lenfosit sayılar, CRP ve ESR düzeyleri incelendi. Bulgular:N/L oranları ve CRP düzeyleri sağlıklı kişilerle kıyaslandığında PH olanlarda istatistiksel olarak anlamlı şekilde yüksek olduğu görüldü, ayrıca N/L oranları ile CRP düzeyleri arasında istatistiksel olarak anlamlı ancak zayıf bir korelasyonun olduğu tespit edildi. Benzer şekilde CRP düzeyleri ile N/L oranları ve Hoehn-Yahr evreleri arasında istatistiksel olarak anlamlı ancak zayıf bir korelasyonun olduğu görüldü. Hasta grubunda N/L oranları ayrı ayrı CRP ve ESR ile korele edildiğinde sadece N/L ile CRP arasında istatistiksel olark anlamlı zayıf bir korelasyon vardı. Sonuç: Çalışmamızda periferik inflamasyonun çok iyi birer göstergeleri olan N/L oranları ve CRP düzeylerinin PH' larında anlamlı olarak daha yüksek olduğunu tespit ettik. Bulgularımız bu markerların PH için tanısal değeri olabilceğini düşündürmektedir

show abstract

Section: Discussionmentioning

confidence: 95%

Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson's disease

Solmaz¹,

Genç²,

Aksoy³

et al. 2018

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…44 C-reactive protein is known to mediate the link between glucose and uric acid 45 and has been shown to be a predictor of life expectancy and death in PD. 46 Further important predictors for faster motor progression were neurofilament light chains in CSF. The neurofilament medium, heavy, and light subunits contribute to the cytoskeleton including axial and dendritic branching and growth.…”

Section: Discussionmentioning

confidence: 99%

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

et al. 2018

View full text Add to dashboard Cite

Objectives The objectives of this study were to investigate (1) the annual rate of progression of motor and cognitive symptoms and (2) baseline predictors of different modalities for this progression in early Parkinson's disease (PD) when compared with healthy controls. Methods A total of 135 de novo PD and 109 healthy controls (of the De Novo Parkinson cohort) were investigated at baseline and after 24 and 48 months. To delineate motor progression and cognitive decline, the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale part III (MDS‐UPDRS III) and the Mini‐Mental Status Examination (MMSE) were selected. Baseline variables used to predict progression included sociodemographic factors, comorbidities, motor/nonmotor symptoms, polysomnography, MRI, and laboratory biomarkers in serum and CSF. Results Symptoms worsened over 4 years in PD with an annual change of 1.8 points on the MDS‐UPDRS III and 0.2 points on the MMSE. Baseline predictors of worse progression of motor symptoms in PD included male sex, orthostatic blood pressure drop, diagnosis of coronary artery disease, arterial hypertension, elevated serum uric acid, and CSF neurofilament light chain. Predictors of cognitive decline in PD included previous heavy alcohol abuse, current diagnoses of diabetes mellitus, arterial hypertension, elevated periodic limb movement index during sleep, decreased hippocampal volume by MRI, higher baseline levels of uric acid, C‐reactive protein, high density lipoprotein (HDL) cholesterol, and glucose levels. Conclusion Cardiovascular risk factors, deregulated blood glucose, uric acid metabolism, and inflammation were identified as risk markers for faster disease progression. Our panel of risk parameters needs validation during our continuing follow‐up and also in independent patient cohorts. © 2018 International Parkinson and Movement Disorder Society

show abstract

“…In a retrospective analysis, patients with Parkinson disease and elevated CRP levels at baseline had a significantly shortened survival compared with those with normal CRP levels. 46 Moreover, CRP has been associated with severity of functional impairment in other neuromuscular disorders. In particular, in patients with Duchenne muscular dystrophy, high levels of CRP (mean, 3.94 md/dL) were associated with poor functional impairment and obesity.…”

Section: Discussionmentioning

confidence: 99%

Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

et al. 2017

View full text Add to dashboard Cite

IMPORTANCE Various factors have been proposed as possible candidates associated with the prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no consensus on which biomarkers are reliable prognostic factors. C-reactive protein (CRP) is a biomarker of the inflammatory response that shows significant prognostic value for several diseases. OBJECTIVE To examine the prognostic significance of CRP in ALS. DESIGN, SETTING, AND PARTICIPANTS Patients' serum CRP levels were evaluated from January 1, 2009, to June 30, 2015, in a large cohort of patients with ALS observed by an Italian tertiary multidisciplinary center. Results were replicated in an independent cohort obtained from a population-based registry of patients with ALS. A post hoc analysis was performed of the phase 2 trial of NP001 to determine whether stratification by levels of CRP improves differentiation of responders and nonresponders to the drug. MAIN OUTCOMES AND MEASURES Serum CRP levels from the first examination were recorded to assess their effect on disease progression and survival. RESULTS A total of 394 patients with ALS (168 women and 226 men; mean [SD] age at diagnosis, 60.18 [13.60] years) were observed in a tertiary multidisciplinary center, and the analysis was replicated in an independent cohort of 116 patients with ALS (50 women and 66 men; mean [SD] age at diagnosis, 67.00 [10.74] years) identified through a regional population-based registry. Serum CRP levels in the 394 patients with ALS correlated with severity of functional impairment, as measured by total score on the ALS Functional Rating Scale-Revised, at first evaluation (r =-0.14818; P = .004), and with patient survival (hazard ratio, 1.129; 95% CI, 1.033-1.234; P = .007). Similar results were found in the independent cohort (hazard ratio, 1.044; 95% CI, 1.016-1.056; P Յ .001). Moreover, a post hoc analysis of the phase 2 trial of NP001 using the same CRP threshold showed that patients with elevated baseline CRP levels receiving the higher dose of NP001 had significantly less functional impairment after the treatment period compared with patients with normal baseline CRP, regardless of whether patients with normal CRP levels received NP001 or placebo (3.00 [3.62] vs-7.31 [6.23]; P = .04). CONCLUSIONS AND RELEVANCE These findings suggest that patients with ALS and elevated serum CRP levels progress more rapidly than do those with lower CRP levels and that this elevation may reflect a neuroinflammatory state potentially responsive to the immune regulators such as NP001.

show abstract

Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease

Cited by 55 publications

References 45 publications

Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson's disease

Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson's disease

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About